AURIGA PROJECTS $26.4 MIL REVENUE FOR CALENDAR YR 2006.

Auriga Laboratories, Inc. (OTCBB:ARGA), Norcross, Ga., a specialty pharmaceutical company formed to drive high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has released revenue guidance for the remainder of calendar year 2006 and for 2007, projecting significant revenue increases through sales growth of its FDA-authorized prescription drug products, including Extendryl and other brands.

Auriga currently projects that it will generate an estimated $26.4 million of total revenue for the calendar year ending December 31, 2007, compared to total revenues of an estimated $7.6 million currently projected for the calendar year ending December 31, 2006, according to guidance just released by Philip S. Pesin, Auriga's CEO. Auriga generated approximately $507,000 of revenues during the three months ended June 30, 2006. Auriga generated $3.7 million of net losses during such three month period and anticipates that it will continue to generate losses until sometime in 2007.

We are extraordinarily pleased to announce these forecasts which we believe are based on a realistic reflection of the marketplace value and strength of Auriga's business model and vision" said Pesin. "It should be clear to the investment community that Auriga has already made very substantial progress in the execution of its high-growth business path, most recently validated, we believe, by a series of key acquisitions and other strategic milestones. We are extremely excited by the successes we have achieved so far and by the outlook for the remainder of 2006 and for 2007."

The revenue forecasts are based on a number of assumptions and other factors, including historical sales of Extendryl and Levall, projected demand for the newly FDA-cleared product Aquoral and our ability to increase our commissioned sales force.

Auriga is targeting the multibillion-dollar cold, respiratory and allergy markets through its Extendryl and Levall families of prescription drug products. It also recently announced the acquisition of the exclusive license to market the FDA-cleared Aquoral, a prescription-only product designed to treat the widespread condition xerostomia, representing a potential marketplace estimated to exceed $1 billion. In addition, in an effort to maximize sales revenues, Auriga has also launched an innovative commission-only structure designed to enable Auriga to enlarge its sales force significantly during the next 18 months, while minimizing fixed costs. Based on its current business plan, Auriga estimates that the sales force could grow to in excess of 100 representatives within 18 months, compared to the current sales force of 30 representatives.

Since last year, Auriga has bolstered its product portfolio following the milestone acquisitions of exclusive distribution rights to Extendryl, Levall and Aquoral. The company intends to continue to acquire new prescription drug brands. It also plans to extend existing brands with proprietary drug-delivery technology and to further develop its pipeline of new drug candidates.

Auriga develops pharmaceutical products based on patented drug delivery technologies that match an understanding of patient physiology with advances in cellular biology, material science, and pharmaceutics. Its business strategy has been designed to minimize the capital requirements, risk and product time-to-market through the acquisition and reformulation of undervalued products for extended market exclusivity.

About Auriga Laboratories(TM)

Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl and Levall families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the company will seek to acquire and/or in-license additional products and technologies to further grow revenues.

For more information, visit http://www.aurigalabs.com or call 877/287-4428.